Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib
Not yet recruiting
- Conditions
- NSCLC
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06644495
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI
Phase 3
Not yet recruiting
- Conditions
- Intra-abdominal Infections
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 786
- Registration Number
- NCT06633718
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
Phase 4
Recruiting
- Conditions
- Chemotherapy-Induced Febrile Neutropenia
- Interventions
- Drug: QL0605(PEG-rhG-CSF)
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 336
- Registration Number
- NCT06616571
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, Shandong, China
A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 198
- Registration Number
- NCT06614907
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
Phase 1
Not yet recruiting
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Drug: QLS4131 Injection
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06500507
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
Phase 2
Not yet recruiting
- Conditions
- Cancer Treatment-Induced Thrombocytopenia
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 235
- Registration Number
- NCT06456528
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
Phase 2
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06446388
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis
Phase 3
Recruiting
- Conditions
- Lupus Nephritis
- Interventions
- Drug: Voclosporin（QL1074）Drug: Placebo
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 270
- Registration Number
- NCT06406205
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
🇨🇳The People's Hospital of Bozhou, Bozhou, Anhui, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Colorectal CancerPancreatic CancerNon-small Cell Lung CancerSolid Tumor
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT06403735
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
🇨🇳Harbin Medical university cancer hospital, Ha'erbin, Heilongjiang, China
🇨🇳Jiangxi Cancer Hospital, Nanchang, Jiangxi, China
A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignant Neoplasm
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06394713